# A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

> **NCT07192614** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 52 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** AZD6621

## Key facts

- **NCT ID:** NCT07192614
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2029-03-29
- **Final completion:** 2029-03-29
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07192614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07192614, "A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07192614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*